Insulinomas, the most common cause of hypoglycemia related to endogenous
hyperinsulinism, occur in 1-4 people per million of the general population. Common …

Neuroendocrine tumors (NETs) constitute a heterogeneous group of neoplasms that
originate from endocrine glands such as the pituitary, the parathyroids, and the …

This ENETS guidance paper aims to provide practical advice to clinicians for the diagnosis,
treatment and follow‐up of functioning syndromes in pancreatic neuroendocrine tumours …

Gastrinomas are neuroendocrine neoplasms, usually located in the duodenum or pancreas,
that secrete gastrin and cause a clinical syndrome known as Zollinger-Ellison syndrome …

Biomarkers have been the mainstay in the diagnosis and follow-up of patients with
neuroendocrine tumors (NETs) over the last few decades. In the beginning, secretory …

Neuroendocrine tumors (NETs) are rare, slow-growing neo-plasms characterized by their
ability to store and secrete different peptides and neuroamines. 1 Some of these substances …

Tumors of mesenchymal and epithelial origin produce IGF-2, which activates pathways in
the tumors. In a minority of patients, the tumors (hepatomas, fibromas, and fibrosarcomas are …

Neuroendocrine tumours (NETs) are neoplasms that arise from neuroendocrine cells.
Neuroendocrine cells and their tumours can secrete a wide range of amines and …

The overall sensitivity and specificity of urinary 5-HIAA in the presence of the carcinoid
syndrome is of the order of 70 and 90%, respectively [1, 2]. Midgut carcinoids are most liable …

Glucagon-like peptide-1 (GLP-1) receptor imaging is superior to somatostatin receptor
subtype 2 (sst2) imaging in localizing benign insulinomas. Here, the role of GLP-1 and sst2 …